Drug profile · INN
adalimumab-aaty
YUFLYMA
adalimumab-aaty (YUFLYMA) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — adalimumab-aaty
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
adalimumab-aaty (YUFLYMA) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
TNF-alpha inhibitor
Primary target: Tumor necrosis factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is adalimumab-aaty?
adalimumab-aaty (YUFLYMA) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for adalimumab-aaty?
YUFLYMA is a marketed brand name for adalimumab-aaty. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of adalimumab-aaty?
adalimumab-aaty has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.